148430-81-3

Basic information

• Product Name: Oxetan-3-yl Methanesulfonate
• Synonyms: Oxetan-3-yl Methanesulfonate;3-Oxetanol 3-Methanesulfonate
• CAS NO: 148430-81-3
• Molecular Formula: C₄H₈O₄S
• Molecular Weight: 152.16892
• Mol File: 148430-81-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 308.9±31.0 °C(Predicted)
• Appearance: /
• Density: 1.38±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Oxetan-3-yl Methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: Oxetan-3-yl Methanesulfonate(148430-81-3)
• EPA Substance Registry System: Oxetan-3-yl Methanesulfonate(148430-81-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 148430-81-3(Hazardous Substances Data)

Usage

General Description

Oxetan-3-yl methanesulfonate is a chemical compound with the formula C5H10O3S. It is an organic sulfonate ester that is used as a reagent in organic synthesis and as a protecting group for alcohols and amines. The compound is known for its ability to selectively protect hydroxyl groups in the presence of other functional groups, making it a valuable tool in the field of organic chemistry. Its versatile reactivity and stability make it an important building block for the synthesis of complex organic molecules in drug discovery and other industrial applications.

Upstream product

• 26272-83-3 oxetan-3-yl 4-methylbenzenesulfonate 
• 75-75-2 methanesulfonic acid 
• 7748-36-9 oxetan-3-ol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1339890-99-1 1-(oxetan-3-yl)-4-((4,4,5,5-tetramethyl)-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1369534-96-2 3-(4-bromophenoxy)oxetane 
• 1431873-42-5 C₂₁H₁₉FN₆O₃ 
• 1431873-44-7 C₂₀H₁₉FN₆O₂ 

Relevant articles and documents

Mild C–C Bond Formation via Lewis Acid Catalyzed Oxetane Ring Opening with Soft Carbon Nucleophiles

Mild oxetane opening by soft carbon nucleophiles has been developed for efficient C?C bond formation. In the presence of LiNTf2 or TBSNTf2 as catalyst, silyl ketene acetals were found to be effective nucleophiles to generate a wide range of highly oxygenated molecules, which are key substructure in natural products like polyketides. Furthermore, intramolecular oxetane opening by a styrene-based carbon nucleophile via a Prins-type process was also achieved with Sc(OTf)3 as catalyst, leading to efficient formation of the useful 2,3-dihydrobenzo[b]oxepine skeleton.

N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists

CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurological abnormalities in the central nervous system (CNS). Herein, we describe the discovery of a novel 1-cyclopentenyl-3-phenylurea series as potent and CNS penetrant CXCR2 antagonists. Extensive SAR studies, wherein molecules' property forecast index (PFI) was carefully optimized for overall balanced developability profiles, led to the discovery of the advanced lead compound 68 with a desirable PFI. Compound 68 demonstrated good in vitro pharmacology with excellent selectivity over CXCR1 and other chemokine receptors. Rat and dog pharmacokinetics (PK) revealed good oral bioavailability, high oral exposure, and desirable elimination half-life of the compound in both species. In addition, the compound demonstrated dose-dependent efficacy in the in vivo pharmacology neutrophil infiltration "air pouch" model in rodents after oral administration. Further, compound 68 is a CNS penetrant molecule with high unbound fraction in brain tissue.